3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Solid Tumors
1
Ovarian Cancer Recurrent
1
Interventions
Paclitaxel
3
liposomal doxorubicin
2
Carboplatin
2
1-dodecylpyridoxal
2
pembrolizumab
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Bevacizumab
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Cancer Recurrent
×
EP-100 membrane-disrupting peptide
×
Clear all
NCT01485848
2014-06-10
ESP2011-002
Esperance Pharmaceuticals Inc
Phase 2
Completed
49 enrolled